642 related articles for article (PubMed ID: 9030120)
21. Management of complications following leprosy: an evolving scenario.
Sehgal VN; Sardana K; Dogra S
J Dermatolog Treat; 2007; 18(6):366-74. PubMed ID: 18058495
[TBL] [Abstract][Full Text] [Related]
22. [Histoid leprosy with erythema nodosum leprosum].
Alioua Z; Sbai M; Elhaouri M; Bouzidi A; Boudi O; Ghfir M; Benomar S; Sedrati OL
Acta Leprol; 2003; 12(3):107-11. PubMed ID: 15040700
[TBL] [Abstract][Full Text] [Related]
23. Unexplained delayed nerve impairment in leprosy after treatment.
Rosenberg NR; Faber WR; Vermeulen M
Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
[TBL] [Abstract][Full Text] [Related]
24. No role for thalidomide in the treatment of leprosy.
Crawford CL
J Infect Dis; 2006 Jun; 193(12):1743-4; author reply 1744-5. PubMed ID: 16703522
[No Abstract] [Full Text] [Related]
25. Severe vasculonecrotic erythema nodosum leprosum following thalidomide withdrawal without tapering doses: do we have something unusual?
Mahajan VK; Chauhan PS; Sharma NL; Sharma AL; Mehta KS
Braz J Infect Dis; 2011; 15(1):90-1. PubMed ID: 21412598
[No Abstract] [Full Text] [Related]
26. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy.
Rao PS; Sugamaran DS; Richard J; Smith WC
Lepr Rev; 2006 Mar; 77(1):25-33. PubMed ID: 16715687
[TBL] [Abstract][Full Text] [Related]
27. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
28. Erythema nodosum leprosum in subgroups of lepromatous leprosy.
Bhargava P; Kuldeep CM; Mathur NK
Lepr Rev; 1997 Dec; 68(4):373-5. PubMed ID: 9503874
[No Abstract] [Full Text] [Related]
29. Clinicopathologic challenge.
Kawakami T; Tsutsumi Y; Mizoguchi M; Ishi N; Soma Y
Int J Dermatol; 2007 Apr; 46(4):348-9. PubMed ID: 17442070
[No Abstract] [Full Text] [Related]
30. Annular vesiculobullous eruptions in type 2 reaction in borderline lepromatous leprosy: a case report.
Kar HK; Raina A; Sharma PK; Bhardwaj M
Indian J Lepr; 2009; 81(4):205-8. PubMed ID: 20704077
[TBL] [Abstract][Full Text] [Related]
31. Leprosy reactions. New knowledge.
Naafs B
Trop Geogr Med; 1994; 46(2):80-4. PubMed ID: 8079395
[No Abstract] [Full Text] [Related]
32. [Bullous erythema nodosum leprosum. A case report in French Guiana].
Couppié P; Sainte-Marie D; About V; Heid E; Pradinaud R
Ann Dermatol Venereol; 1998 Mar; 125(3):188-90. PubMed ID: 9747246
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate in resistant ENL.
Kar BR; Babu R
Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):480-2. PubMed ID: 15755203
[TBL] [Abstract][Full Text] [Related]
34. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Costa PDSS; Fraga LR; Kowalski TW; Daxbacher ELR; Schuler-Faccini L; Vianna FSL
Acta Trop; 2018 Jul; 183():134-141. PubMed ID: 29474830
[TBL] [Abstract][Full Text] [Related]
35. [Leprosy and the testis].
Rodríguez G; Abaúnza MC; Vargas EJ; López F
Biomedica; 2012; 32(1):13-22. PubMed ID: 23235783
[TBL] [Abstract][Full Text] [Related]
36. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
37. Etanercept in erythema nodosum leprosum.
Santos JRS; Vendramini DL; Nery JADC; Avelleira JCR
An Bras Dermatol; 2017; 92(4):575-577. PubMed ID: 28954119
[TBL] [Abstract][Full Text] [Related]
38. Does thalidomide have a role in leprosy?
Crawford CL
Lancet; 2004 Jun; 363(9424):1911. PubMed ID: 15183644
[No Abstract] [Full Text] [Related]
39. Reactions and their management.
Ganapati R; Pai VV
J Indian Med Assoc; 2004 Dec; 102(12):688-90, 692, 694. PubMed ID: 15871353
[TBL] [Abstract][Full Text] [Related]
40. [Late reversal leprous reaction appearing 18 months after the termination of treatment].
Bourée P; de Brette A; de Carsalade GY
Presse Med; 2001 Mar; 30(8):376. PubMed ID: 11268894
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
